JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

Search

Xenon Pharmaceuticals Inc

Cerrado

SectorSalud

30.51 0.07

Resumen

Variación precio

24h

Actual

Mínimo

30

Máximo

30.7

Métricas clave

By Trading Economics

Ingresos

638K

-65M

Ventas

7.5M

7.5M

Margen de beneficio

-867.293

Empleados

316

EBITDA

4.1M

-73M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 meses

+80.83% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

-369M

2.4B

Apertura anterior

30.44

Cierre anterior

30.51

Noticias sobre sentimiento de mercado

By Acuity

75%

25%

350 / 375 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Xenon Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

31 jul 2025, 23:56 UTC

Acciones populares

Stocks to Watch: Amazon, Bio-Rad, Coinbase, Mercer

31 jul 2025, 23:48 UTC

Charlas de Mercado

Scentre Can Beat Annual Earnings Guidance -- Market Talk

31 jul 2025, 23:45 UTC

Charlas de Mercado

Nikkei May Decline Amid Caution Over Earnings, Domestic Politics -- Market Talk

31 jul 2025, 23:37 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

31 jul 2025, 23:37 UTC

Charlas de Mercado

Gold Steady as Traders Eye Tariff-Deal Developments -- Market Talk

31 jul 2025, 23:12 UTC

Ganancias

OCBC: Evolving Trade, Monetary Policies, Persistent Geopolitical Tensions Expected to Weigh on Growth Prospects >O39.SG

31 jul 2025, 23:10 UTC

Ganancias

Oversea-Chinese Banking: Declining Interest-Rate Environment Weighed in Net Interest Income >O39.SG

31 jul 2025, 23:09 UTC

Ganancias

Oversea-Chinese Banking 2Q Net Interest Income S$2.28B Vs. S$2.43B >O39.SG

31 jul 2025, 23:08 UTC

Ganancias

Oversea-Chinese Banking 2Q Total Income S$3.55B Vs. S$3.63B >O39.SG

31 jul 2025, 23:08 UTC

Ganancias

Oversea-Chinese Banking 2Q Net S$1.82B Vs. Net S$1.94B >O39.SG

31 jul 2025, 23:01 UTC

Ganancias

Amazon Posts Higher Sales, Profit -- 3rd Update

31 jul 2025, 22:08 UTC

Charlas de Mercado
Ganancias

Amazon CEO Impressed by Deals Signed for Project Kuiper -- Market Talk

31 jul 2025, 22:02 UTC

Charlas de Mercado
Ganancias

Apple's FY Outlook Shows Sales Growth Won't Last -- Market Talk

31 jul 2025, 21:57 UTC

Charlas de Mercado
Ganancias

Amazon CEO Sees Strong Early Demand for Alexa+ -- Market Talk

31 jul 2025, 21:50 UTC

Ganancias

Amazon Earnings Beat Expectations. Why the Stock Is Falling. -- Barrons.com

31 jul 2025, 21:43 UTC

Ganancias

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- 2nd Update

31 jul 2025, 21:29 UTC

Ganancias

Amazon to Invest More in Chips, Data Centers Amid Generative AI Opportunity, CFO Says

31 jul 2025, 21:26 UTC

Ganancias

Apple Expects Revenue to Grow in Mid- to High-Single Digits in Current Quarter, CFO Says

31 jul 2025, 21:26 UTC

Ganancias

MicroStrategy Beats Earnings Estimates. The Stock Rises. -- Barrons.com

31 jul 2025, 21:22 UTC

Ganancias

Amazon Has Impressive Amount of Agreements for Project Kuiper, CEO Says

31 jul 2025, 21:19 UTC

Ganancias

Apple Estimates Tariff Impact to Add $1.1B to Costs in Current Quarter, CEO Says

31 jul 2025, 21:19 UTC

Ganancias

Apple Incurred $800M in Tariff-Related Costs in 2Q, CEO Says

31 jul 2025, 21:14 UTC

Ganancias

Amazon's AWS is Seeing More Demand Than Supply, CEO Says

31 jul 2025, 21:12 UTC

Ganancias

Amazon Saw Record Prime Sign-Ups in 3 Weeks Before Prime Day, CEO Says

31 jul 2025, 21:10 UTC

Ganancias

Amazon Just Getting Started on Automation, Robotics to Boost Efficiency, CEO Says

31 jul 2025, 21:09 UTC

Ganancias

Amazon Delivered to Prime Members at Record Pace in 2Q, CEO Says

31 jul 2025, 21:09 UTC

Ganancias

Amazon CEO Sees Diversity of Sellers as Advantage for Inflation-Weary Consumers

31 jul 2025, 21:08 UTC

Ganancias

Apple iPhone Revenue Performance Driven by Popularity of iPhone 16 Family, CEO Says

31 jul 2025, 21:08 UTC

Ganancias

Amazon CEO Sees Strong Customer Adoption of Perishables Same-Day Delivery Pilot

31 jul 2025, 21:05 UTC

Ganancias

Apple's iPhone Sales Blow Past Estimates as Customers Raced to Beat Tariffs -- Update

Comparación entre iguales

Cambio de precio

Xenon Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

80.83% repunte

Estimación a 12 meses

Media 55.64 USD  80.83%

Máximo 65 USD

Mínimo 47 USD

De acuerdo con 14 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Xenon Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

14 ratings

14

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

34.81 / 38.24Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Neutral Evidence

Sentimiento

By Acuity

350 / 375 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Xenon Pharmaceuticals Inc

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.